Observational studyInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2026
Pneumococcal serotype distribution and outcomes in cancer patients with community-acquired pneumonia: A prospective study using the 15-valent pneumococcal conjugate vaccine serotype specific urinary antigen detection assay.
Observational study in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Breaking resistance: strategies for novel antibacterial therapeutic interventions.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesCancer patients with pneumococcal community-acquired pneumonia (CAP) have higher mortality than the general population. Data on pneumococcus serotype distribution in this population are limited. We evaluated pneumococcal serotypes using a 15-valent pneumococcal conjugate vaccine (PCV15) serotype-specific urinary antigen detection (SSUAD) in cancer patients with CAP.
methodsProspective observational study in adult cancer patients with CAP at MSKCC (1/1/2023-1/31/2024). Streptococcal urine antigen (SUA) testing was performed in-house. Remnant urine samples were tested by PCV-15 SSUAD at Q2 laboratories. Blood and respiratory culture results were captured within 7 days of SUA.
resultsOf 912 patients with CAP (median age=67), 94.6% were hospitalized. Forty-one (4.5%) had pneumococcal pneumonia by SUA and SSUAD (N = 35), sputum culture (N = 2), or blood culture (N = 7). By urine antigen, SUA was positive in 15, SSUAD in 19, and one in both. The most common serotype by SSUAD was 7F (24.3%), and 35% had ≥2 serotypes. Only 26.9% had received any pneumococcal vaccine. The overall 30-day mortality was 20.2% with CAP, and 31.7% among patients with pneumococcal pneumonia.
conclusionSerotype 7F, covered by all pneumococcal vaccines, was the most common serotype. The high 30-day all-cause mortality highlights the substantial burden of CAP in cancer patients. Enhanced serotype surveillance and vaccine-effectiveness studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.